Selected research
Industry Research
Bendamustine Injection Industry Research Report 2026
Market perspective
The global Bendamustine Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Bendamustine Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Bendamustine Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Bendamustine Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Bendamustine Injection include Eagle Pharmaceuticals, Emcure, Miracalus Pharma, MundiPharma, Natco Pharma, Mylan, Teva and Eisai, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Bendamustine Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bendamustine Injection Market by Company
Eagle Pharmaceuticals
Emcure
Miracalus Pharma
MundiPharma
Natco Pharma
Mylan
Teva
Eisai
Bendamustine Injection Segment by Type
25mg Injection
100mg Injection
Others
Bendamustine Injection Segment by Application
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Multiple Myeloma
Others
Bendamustine Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bendamustine Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bendamustine Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bendamustine Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bendamustine Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bendamustine Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bendamustine Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 25mg Injection
- 100mg Injection
- Others
Applications
- Chronic Lymphocytic Leukemia
- Non-Hodgkin's Lymphoma
- Multiple Myeloma
- Others
Companies covered
- Eagle Pharmaceuticals
- Emcure
- Miracalus Pharma
- MundiPharma
- Natco Pharma
- Mylan
- Teva
- Eisai
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Bendamustine Injection Market Size (2021-2032)
- 2.2.2 Global Bendamustine Injection Sales (2021-2032)
- 2.2.3 Global Bendamustine Injection Market Average Price (2021-2032)
- 2.3 Bendamustine Injection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 25mg Injection
- 2.3.3 100mg Injection
- 2.3.4 Others
- 2.4 Bendamustine Injection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Chronic Lymphocytic Leukemia
- 2.4.3 Non-Hodgkin's Lymphoma
- 2.4.4 Multiple Myeloma
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Bendamustine Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Bendamustine Injection Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Bendamustine Injection Revenue of Manufacturers (2021-2026)
- 3.4 Global Bendamustine Injection Average Price by Manufacturers (2021-2026)
- 3.5 Global Bendamustine Injection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Bendamustine Injection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Bendamustine Injection, Product Type & Application
- 3.8 Global Manufacturers of Bendamustine Injection, Established Date
- 3.9 Global Bendamustine Injection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Eagle Pharmaceuticals
- 4.1.1 Eagle Pharmaceuticals Company Information
- 4.1.2 Eagle Pharmaceuticals Business Overview
- 4.1.3 Eagle Pharmaceuticals Bendamustine Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Eagle Pharmaceuticals Bendamustine Injection Product Portfolio
- 4.1.5 Eagle Pharmaceuticals Recent Developments
- 4.2 Emcure
- 4.2.1 Emcure Company Information
- 4.2.2 Emcure Business Overview
- 4.2.3 Emcure Bendamustine Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Emcure Bendamustine Injection Product Portfolio
- 4.2.5 Emcure Recent Developments
- 4.3 Miracalus Pharma
- 4.3.1 Miracalus Pharma Company Information
- 4.3.2 Miracalus Pharma Business Overview
- 4.3.3 Miracalus Pharma Bendamustine Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Miracalus Pharma Bendamustine Injection Product Portfolio
- 4.3.5 Miracalus Pharma Recent Developments
- 4.4 MundiPharma
- 4.4.1 MundiPharma Company Information
- 4.4.2 MundiPharma Business Overview
- 4.4.3 MundiPharma Bendamustine Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 MundiPharma Bendamustine Injection Product Portfolio
- 4.4.5 MundiPharma Recent Developments
- 4.5 Natco Pharma
- 4.5.1 Natco Pharma Company Information
- 4.5.2 Natco Pharma Business Overview
- 4.5.3 Natco Pharma Bendamustine Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Natco Pharma Bendamustine Injection Product Portfolio
- 4.5.5 Natco Pharma Recent Developments
- 4.6 Mylan
- 4.6.1 Mylan Company Information
- 4.6.2 Mylan Business Overview
- 4.6.3 Mylan Bendamustine Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Mylan Bendamustine Injection Product Portfolio
- 4.6.5 Mylan Recent Developments
- 4.7 Teva
- 4.7.1 Teva Company Information
- 4.7.2 Teva Business Overview
- 4.7.3 Teva Bendamustine Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Teva Bendamustine Injection Product Portfolio
- 4.7.5 Teva Recent Developments
- 4.8 Eisai
- 4.8.1 Eisai Company Information
- 4.8.2 Eisai Business Overview
- 4.8.3 Eisai Bendamustine Injection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eisai Bendamustine Injection Product Portfolio
- 4.8.5 Eisai Recent Developments
5 Global Bendamustine Injection Market Scenario by Region
- 5.1 Global Bendamustine Injection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Bendamustine Injection Sales by Region: 2021-2032
- 5.2.1 Global Bendamustine Injection Sales by Region: 2021-2026
- 5.2.2 Global Bendamustine Injection Sales by Region: 2027-2032
- 5.3 Global Bendamustine Injection Revenue by Region: 2021-2032
- 5.3.1 Global Bendamustine Injection Revenue by Region: 2021-2026
- 5.3.2 Global Bendamustine Injection Revenue by Region: 2027-2032
- 5.4 North America Bendamustine Injection Market Facts & Figures by Country
- 5.4.1 North America Bendamustine Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Bendamustine Injection Sales by Country (2021-2032)
- 5.4.3 North America Bendamustine Injection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Bendamustine Injection Market Facts & Figures by Country
- 5.5.1 Europe Bendamustine Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Bendamustine Injection Sales by Country (2021-2032)
- 5.5.3 Europe Bendamustine Injection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Bendamustine Injection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Bendamustine Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Bendamustine Injection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Bendamustine Injection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Bendamustine Injection Market Facts & Figures by Country
- 5.7.1 South America Bendamustine Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Bendamustine Injection Sales by Country (2021-2032)
- 5.7.3 South America Bendamustine Injection Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.7.7 Colombia
- 5.8 Middle East and Africa Bendamustine Injection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Bendamustine Injection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Bendamustine Injection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Bendamustine Injection Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Bendamustine Injection Sales by Type (2021-2032)
- 6.1.1 Global Bendamustine Injection Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Bendamustine Injection Sales Market Share by Type (2021-2032)
- 6.2 Global Bendamustine Injection Revenue by Type (2021-2032)
- 6.2.1 Global Bendamustine Injection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Bendamustine Injection Revenue Market Share by Type (2021-2032)
- 6.3 Global Bendamustine Injection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Bendamustine Injection Sales by Application (2021-2032)
- 7.1.1 Global Bendamustine Injection Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Bendamustine Injection Sales Market Share by Application (2021-2032)
- 7.2 Global Bendamustine Injection Revenue by Application (2021-2032)
- 7.2.1 Global Bendamustine Injection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Bendamustine Injection Revenue Market Share by Application (2021-2032)
- 7.3 Global Bendamustine Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Bendamustine Injection Value Chain Analysis
- 8.1.1 Bendamustine Injection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Bendamustine Injection Production Mode & Process
- 8.2 Bendamustine Injection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Bendamustine Injection Distributors
- 8.2.3 Bendamustine Injection Customers
9 Global Bendamustine Injection Analyzing Market Dynamics
- 9.1 Bendamustine Injection Industry Trends
- 9.2 Bendamustine Injection Industry Drivers
- 9.3 Bendamustine Injection Industry Opportunities and Challenges
- 9.4 Bendamustine Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst